Published: 30 November 2021
Author(s): Francesco Menichetti, Marco Falcone, Giusy Tiseo
Section: Clinical Insights
Immunotherapy with convalescent plasma (CP) has been used in the past in several infectious diseases (influenza, SARS, MERS) with the aim to shorten or stop the phase of viral replication and to improve the patient outcome. However, a clear benefit was never demonstrated.